Onxeo – executive interview

Published on 15 December 2020

Onxeo has a proprietary platON platform based on a unique decoy technology in the field of DNA damage repair inhibition. The lead asset, AsiDNA, is in a Phase Ib triple combination trial with chemotherapy in solid tumours and a second Phase Ib/II trial that aims to demonstrate AsiDNA’s potential to abrogate tumour resistance to PARP inhibitors. The second compound, OX401, is in late preclinical development, optimised to target PARP and is capable of activating the STING pathway. In this video, the CEO of Onxeo Judith Greciet provides an update on the company’s activities and upcoming newsflow.

Share this with friends and colleagues